PARP1 and cancer: These findings clearly warrant further preclinical development of the lead inhibitor, 4-([1,4′-bipiperidine]-1′-carbonyl)-7-fluoro-3,4-dihydroisoquinolin-1(2H)-one, as the novel PARP1/2 inhibitor for the treatment of cancer.